Literature DB >> 19937425

[Aspects of surgical treatment for gastro-intestinal stromal tumors].

P Hohenberger1.   

Abstract

Gastro-intestinal stromal tumors (GIST) form the commonest subgroup of soft tissue sarcomas. They arise in the muscular layer of the esophagus, stomach, small intestines and rectum. Characteristic and important for the assessment of the extent of tumors is the peripheral rim vascularization of primary tumors and metastases. Indications for resection are given for tumors larger than 2 cm in size. Locally advanced GISTs can be advantageously treated with imatinib/sunitinib as neoadjuvant and it is often possible to select a low level of resection for this size of tumor and when the rim area is not hypervascularized. Even in the metastasizing stage surgical treatment can be used for elimination of resistant metastases or for removal of residual tumor tissue in an attempt to counteract secondary tumor progression. The effect of this treatment is currently being tested in a randomized phase III study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937425     DOI: 10.1007/s00117-009-1853-8

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  31 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate.

Authors:  B K P Goh; P K H Chow; K L Chuah; W M Yap; W K Wong
Journal:  Eur J Surg Oncol       Date:  2006-07-12       Impact factor: 4.424

3.  Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.

Authors:  T Heinicke; E Wardelmann; T Sauerbruch; H J Tschampa; A Glasmacher; H Palmedo
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

4.  Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

Authors:  Alessandro Gronchi; Marco Fiore; Francesca Miselli; Maria Stefania Lagonigro; Paola Coco; Antonella Messina; Silvana Pilotti; Paolo Giovanni Casali
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

5.  Lessons learned from laparoscopic treatment of gastric and gastroesophageal junction stromal cell tumors.

Authors:  S R Granger; M D Rollins; S J Mulvihill; R E Glasgow
Journal:  Surg Endosc       Date:  2006-07-24       Impact factor: 4.584

6.  Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Authors:  Robert H I Andtbacka; Chaan S Ng; Courtney L Scaife; Janice N Cormier; Kelly K Hunt; Peter W T Pisters; Raphael E Pollock; Robert S Benjamin; Michael A Burgess; Lei L Chen; Jonathan Trent; Shreyaskumar R Patel; Kevin Raymond; Barry W Feig
Journal:  Ann Surg Oncol       Date:  2007-01       Impact factor: 5.344

7.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

Review 8.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Authors:  Jean-Yves Blay; Axel Le Cesne; Isabelle Ray-Coquard; Binh Bui; Florence Duffaud; Catherine Delbaldo; Antoine Adenis; Patrice Viens; Maria Rios; Emmanuelle Bompas; Didier Cupissol; Cecile Guillemet; Pierre Kerbrat; Jérome Fayette; Sylvie Chabaud; Patrice Berthaud; David Perol
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

10.  The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction.

Authors:  Wilko I Staiger; Ulrich Ronellenfitsch; Georg Kaehler; Hans Ulrich Schildhaus; Antonia Dimitrakopoulou-Strauss; Matthias Hm Schwarzbach; Peter Hohenberger
Journal:  World J Surg Oncol       Date:  2008-04-04       Impact factor: 2.754

View more
  1 in total

Review 1.  Characteristics of gastrointestinal stromal tumours, diagnostic procedure and therapeutic management and main directions of nursing practice in gastrointestinal stromal tumours.

Authors:  Grażyna R Wiraszka; Stanisław Głuszek; Dorota Kozieł
Journal:  Contemp Oncol (Pozn)       Date:  2014-05-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.